Dr. Heinz-Josef Lenz
Claim this profileUSC / Norris Comprehensive Cancer Center
Expert in Colorectal Cancer
Expert in Adenocarcinoma
33 reported clinical trials
61 drugs studied
Area of expertise
1Colorectal Cancer
Global LeaderStage IV
Stage III
BRAF negative
2Adenocarcinoma
Global LeaderStage IV
BRAF negative
Stage III
Affiliated Hospitals
Clinical Trials Heinz-Josef Lenz is currently running
Tucatinib + Trastuzumab + Chemotherapy
for Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3
TAK-676 + Pembrolizumab
for Metastatic Cancer
This trial is testing a new drug called dazostinag, alone and with another drug called pembrolizumab, to treat people with advanced solid tumors. It focuses on patients with specific types of head and neck cancer and colorectal cancer who have few other treatment options. The goal is to find a safe dose and see if the combination can help the immune system fight the cancer more effectively.
Recruiting2 awards Phase 1 & 210 criteria
More about Heinz-Josef Lenz
Clinical Trial Related6 years of experience running clinical trials · Led 33 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Heinz-Josef Lenz has experience with
- Ipilimumab
- Cetuximab
- Nivolumab
- Bevacizumab
- Regorafenib
- Atezolizumab
Breakdown of trials Heinz-Josef Lenz has run
Colorectal Cancer
Adenocarcinoma
Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Heinz-Josef Lenz specialize in?
Heinz-Josef Lenz focuses on Colorectal Cancer and Adenocarcinoma. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Heinz-Josef Lenz currently recruiting for clinical trials?
Yes, Heinz-Josef Lenz is currently recruiting for 9 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Heinz-Josef Lenz has studied deeply?
Yes, Heinz-Josef Lenz has studied treatments such as Ipilimumab, Cetuximab, Nivolumab.
What is the best way to schedule an appointment with Heinz-Josef Lenz?
Apply for one of the trials that Heinz-Josef Lenz is conducting.
What is the office address of Heinz-Josef Lenz?
The office of Heinz-Josef Lenz is located at: USC / Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States. This is the address for their practice at the USC / Norris Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.